As a treatment, combined therapy of MET-I and HGFA-I showed the strongest inhibition of the phosphorylation of MET and reduced the proliferation and migration of RCC cells in the presence of pro-HGF. The gene discussed is HGF; the disease is renal cell carcinoma.